Government is to review use of copayments in the NHS

O'Dowd, Adrian
June 2008
BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1455
Academic Journal
The article reports that the British government will re-examine a rule that prevents the use of co-payments for the purchase of drugs outside the British National Health Service (NHS). The author notes that patients who purchase drugs outside the NHS are required to pay all costs for their care. He discusses government concerns that the use of co-payments could create multiple service tiers in the NHS and notes that many medical associations support the use of co-payments.


Related Articles

  • Patient co-payments for general practice. Gilbert, Simon // British Journal of General Practice;Jul2015, Vol. 65 Issue 636, p341 

    A letter to the editor is presented in response to the article "Patient co-payment for general practice services: slippery slope or a survival imperative for the NHS?," by L. Toop and C. Jackson in the 2015 issue.

  • "Ever-increasing" NHS drugs bill for diabetes.  // PharmacoEconomics & Outcomes News;9/3/2011, Issue 636, p10 

    The article reports that prescriptions for diabetes drugs account for 8.4% of the total National Health Service (NHS) drugs bill in England, according to the data issued by the NHS Information Centre in 2011.

  • This principle is no longer suitable.  // Optometry Today;6/13/2008, Vol. 48 Issue 12, p18 

    The article focuses on the issue of co-payments in the medical care sector in Great Britain. Health secretary Alan Johnson argued that a government policy of denying National Health Service (NHS) treatment to patients who pay for private medicines is needed in order to stop the two-tier NHS. The...

  • Co-payment Clarke.  // Prospect;Jul2008, Issue 148, p9 

    The article references the political debate over co-payment for medical services provided by Great Britain's National Health Service (NHS). It is reported that Labour Party politician Charles Clarke will release a report on the matter in July 2008 which may suggest that institution of...

  • MPS proposes differential defence rates.  // BMJ: British Medical Journal (International Edition);11/19/88, Vol. 297 Issue 6659, p1289 

    Focuses on the introduction of differential subscription rates by the Medical Protection Society in Great Britain. Emphasis on the financial responsibility of National Health Service; Consideration of limited scheme of no fault compensation for brain damage babies; Rates for junior doctors.

  • GPs voice patient confidentiality concerns. Rogers, James // Computer Weekly;5/20/2003, p19 

    Doctors have voiced concerns about how patient confidentiality can be preserved while maintaining the health service's Integrated Care Records Service. The ICRS is a core component of the British government's 2.3 billion pound national programme to overhaul NHS IT. One of its key functions will...

  • Working together. Douglas, Colin // BMJ: British Medical Journal (International Edition);4/5/2003, Vol. 326 Issue 7392, p771 

    Presents a commentary on the annual dinner of the Medical Curling Club in Scotland. Conversation among guests about the National Health Services paper 'Partnership for Care;' Details of the comments made about the health care profession.

  • How many medicines are there? Snell, Eric S.; Griffin, John P. // British Medical Journal (Clinical Research Edition);3/9/1985, Vol. 290 Issue 6470, p773 

    Examines the proposals for a national limited inventory list of medicines for use in the National Health Service in Great Britain. Variants in defining the medical listing of pharmaceutical products; Aspects of the national licensing system for drugs; Assessments on the estimated number of...

  • Drug companies' lobbying of ministers has little effect on NICE. Jack, Andrew // BMJ: British Medical Journal (International Edition);10/7/2006, Vol. 333 Issue 7571, p719 

    This article reports on drug companies criticizing the National Institute for Health and Clinical Excellence (NICE) in Great Britain. Senior executives from ten drug companies lobbied to overturn the judgment of NICE, a body that advises on the use of treatments by the NHS in Great Britain. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics